Xsolla Founder Shurick Agapitov Releases Once Upon Tomorrow Fortnite Island: A Groundbreaking Immersive Experience That Brings the Novel's Universe to Life
12.12.2024 15:00:00 CET | Business Wire | Press release
High-Octane Parkour Challenges Meet Story-Driven Gameplay in a New Fortnite Creative Map Inspired by Once Upon Tomorrow
Shurick Agapitov, founder of Xsolla and visionary in the gaming industry, proudly announces the Once Upon Tomorrow Fortnite Island release. This immersive Fortnite Creative map transports players into the rich narrative world of his novel. The innovative experience, developed in Unreal Editor for Fortnite (UEFN), masterfully combines high-speed parkour challenges with deep thematic elements from Once Upon Tomorrow, inviting players to test their skills while journeying through a visually captivating landscape that embodies the resilience and adventure of the book’s characters.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212923969/en/
(Graphic: Xsolla)
“Once Upon Tomorrow in Fortnite Creative is our way of expanding the reach and depth of the novel, offering players an interactive journey that challenges both their skills and their understanding of the story’s themes,” said Shurick Agapitov, Founder of Xsolla. “We designed this map to captivate players who crave a good challenge and to immerse them in a world that’s visually rich and deeply inspired by the book. It’s an adventure that leverages UEFN’s technical strengths to elevate storytelling in Fortnite in a way that truly transforms the game experience.”
Designed to push the boundaries of Fortnite Creative, Once Upon Tomorrow offers players a dynamic, narrative-driven parkour adventure set within a meticulously crafted environment inspired by Agapitov’s book and vision. Each course presents a series of agility-based challenges that require players to sprint, leap, and climb with precision and speed, all while immersed in a world filled with visual cues that echo the themes of endurance and discovery central to the book. Agapitov has created an experience beyond traditional parkour maps by weaving gameplay with storytelling, delivering both exhilarating gameplay and a meaningful connection to the novel’s world.
Once Upon Tomorrow is a project within Fortnite Creative, seamlessly blending high-stakes parkour with narrative depth. The map is a testament to what can be achieved using UEFN, offering an engaging and multi-layered experience that appeals to Fortnite’s extensive player base and fans of novel and narrative-rich gaming experiences. Every aspect of the map—from its intense gameplay mechanics to its immersive, atmospheric design—has been crafted to set a new standard in Fortnite Creative.
For more information about Once Upon Tomorrow and its immersive Fortnite Creative experience, please visit xsolla.blog/outf
About Shurick Agapitov
Shurick Agapitov is the visionary founder of Xsolla, a globally recognized leader in video game commerce. Known for his contributions to gaming, Web3, and the metaverse, Agapitov has driven Xsolla to become a vital resource for game developers and publishers worldwide. His dedication to enhancing digital and interactive experiences is reflected in the launch of Once Upon Tomorrow, extending his vision beyond the page to the dynamic world of Fortnite Creative.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world, Xsolla supports leading gaming partners such as Valve, Twitch, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, among others.
For additional information and to learn more, please visit xsolla.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241212923969/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom